Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (81-90 of 159) with videos related to

Pageof 16
Sort By:
Clinical Rheumatology|January 15, 2015
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsDavid Grabowski, Bradley Henderson, Dennis Lam, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
Arthritis and Rheumatism|May 18, 2004
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialEdward C Keystone, Arthur F Kavanaugh, John T Sharp, et al.
The Journal of Rheumatology|October 3, 2014
Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH)Bindee Kuriya, Juan Xiong, Gilles Boire, et al.
The Journal of Rheumatology|November 19, 2013
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extensionEdward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, et al.
The Journal of Rheumatology|April 17, 2012
Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteriaBindee Kuriya, Ye Sun, Gilles Boire, et al.
The Journal of Rheumatology|September 3, 2015
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis CohortJenny Shu, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid ArthritisEdward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Annals of Internal Medicine|May 30, 2017
Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness AnalysisNick Bansback, Ciaran S Phibbs, Huiying Sun, et al.
The Journal of Rheumatology|August 17, 2012
The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activityVivian P Bykerk, Shahin Jamal, Gilles Boire, et al.
Pageof 16

Showing results (81-90 of 159) with videos related to

Sort By:
Pageof 16
Clinical Rheumatology|January 15, 2015
Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsDavid Grabowski, Bradley Henderson, Dennis Lam, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
Arthritis and Rheumatism|May 18, 2004
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialEdward C Keystone, Arthur F Kavanaugh, John T Sharp, et al.
The Journal of Rheumatology|October 3, 2014
Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH)Bindee Kuriya, Juan Xiong, Gilles Boire, et al.
The Journal of Rheumatology|November 19, 2013
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extensionEdward C Keystone, Ferdinand C Breedveld, Désirée van der Heijde, et al.
The Journal of Rheumatology|April 17, 2012
Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteriaBindee Kuriya, Ye Sun, Gilles Boire, et al.
The Journal of Rheumatology|September 3, 2015
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis CohortJenny Shu, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid ArthritisEdward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Annals of Internal Medicine|May 30, 2017
Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness AnalysisNick Bansback, Ciaran S Phibbs, Huiying Sun, et al.
The Journal of Rheumatology|August 17, 2012
The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activityVivian P Bykerk, Shahin Jamal, Gilles Boire, et al.
Pageof 16